Summary of Vir Biotechnology Conference Call Company Overview - **Company**: Vir Biotechnology (NasdaqGS:VIR) - **Focus Areas**: Infectious diseases and oncology, utilizing the human immune system to combat diseases [3][4] Key Strategies and Developments - **Oncology Programs**: - Development of masked T-cell engagers for metastatic solid tumors, with three clinical stage programs [3] - Recent compelling data from the prostate cancer program (VIR-5500) presented at ASCO GU [5] - Ongoing registrational program in hepatitis delta with initial data expected by the end of the year [4] Prostate Cancer Program (VIR-5500) - **Clinical Data**: - Phase 1 trial involved late-stage metastatic prostate cancer patients, many with poor prognoses [5] - Notable patient case: 63-year-old male with extensive liver metastases showed total obliteration of lesions after 9 weeks of treatment [6] - Achieved 53% PSA 90s and 29% PSA 99s in patients treated with doses above 3,000 micrograms per kilogram [7][12] - **Safety Profile**: - Low levels of cytokine release syndrome (CRS) and off-tumor toxicity, indicating a favorable safety profile [11][12] Competitive Landscape - **Differentiation**: - VIR-5500's dual masking technology allows for targeted action in the tumor microenvironment, potentially setting it apart from competitors [10] - Initial focus on late-line therapy with plans to explore earlier lines of therapy in combination with enzalutamide [15][17] Partnership with Astellas - **Deal Highlights**: - 50-50 profit split in the U.S. and co-promotion agreement, aiming for rapid market entry [20] - Financial terms include $1.7 billion in milestones and royalties, with Astellas covering 60% of global development costs [21] Future Plans - **Clinical Trials**: - Plans to skip Phase 2 and move directly to pivotal trials for VIR-5500 next year [24] - Expansion cohorts to begin in Q2 2026 [24] Other Oncology Programs - **HER2 and EGFR Programs**: - HER2 program showed initial signs of activity with 50% tumor shrinkage in a small cohort [36] - EGFR program is in early stages of dose escalation, exploring multiple indications [43] Hepatitis Delta Program - **Efficacy Data**: - 66% of patients reached undetectable levels after 48 weeks; 90% after 96 weeks [48] - Combination regimen of antibody and siRNA shows significant efficacy compared to competitors [50] - **Market Position**: - Anticipation of increased awareness and diagnosis of hepatitis delta due to competitive landscape [49] Financial Position - **Cash Runway**: - Increased cash position with partnerships and financing, providing runway until Q2 2028 [56] - Focus on oncology and hepatitis delta as key priorities while exploring other programs [57] Market Perception - **Company Transformation**: - Transition from a COVID-focused company to an immuno-oncology company, with a strong vision and promising data supporting this shift [58]

Summary of Vir Biotechnology FY Conference Call Company Overview - **Company**: Vir Biotechnology (NasdaqGS:VIR) - **Focus**: Development of innovative therapies for serious diseases, particularly in oncology and infectious diseases Key Developments - **VIR-5500**: - Recent data disclosed showed impressive efficacy and safety profiles in a trial involving very sick patients, with 95% having pre-taxane treatment and a median of 4 prior therapies [2][3] - **Efficacy Metrics**: - PSA50 rate: 82% - PSA90 rate: 53% - PSA99 rate: 29% - RECIST ORR: 45% in a very sick patient population [4] - **Safety Profile**: - Utilizes a PRO-XTEN masking platform to enhance safety by activating T-cells only at the tumor site, allowing for higher dosing without significant toxicity [5][6] Partnership with Astellas - **Strategic Partnership**: - Astellas selected as a partner due to their experience in prostate cancer and alignment on speed to market [16][17] - The deal includes a 50/50 profit split and a total of $1.7 billion in milestones, with $240 million cash upfront [19] - Vir retains significant involvement in the program, allowing for cash flow to support other projects [18] Future Plans - **Expansion Cohorts**: - Plans to initiate expansion cohorts for late-line monotherapy and early-line combination therapies with enzalutamide [11] - Pivotal trials expected to start next year [11] Competitive Landscape - **T-cell Engagers (TCEs)**: - VIR-5500 positioned as a potential best-in-class TCE for prostate cancer, achieving a favorable balance of efficacy and safety compared to competitors [13] - Other TCEs have shown either high efficacy with toxicity issues or mediocre efficacy with good safety profiles [13] Pipeline Overview - **Clinical Assets**: - Licensed three clinical-stage assets from Sanofi, including HER2 (VIR-5818) and EGFR (VIR-5525), both in phase 1 [23] - Seven preclinical assets utilizing the PRO-XTEN technology are progressing rapidly [24] Hepatitis Delta Virus (HDV) Program - **Tobevibart and Elebsiran**: - Combination therapy showed an 88% target not detected rate after 96 weeks, indicating strong efficacy in treating HDV [30] - Registrational trials ongoing, with initial data expected in Q4 2026 [30] Market Opportunity - **HDV Patient Population**: - Estimated 60,000 viremic patients in the U.S. and double that in Europe, with high potential pricing due to the orphan disease status [34] - Pricing estimates range from $150K to $250K in the U.S. and €60,000 to €150,000 in Europe [34] Financial Position - **Cash Balance**: - Post-Astellas deal, cash balance is $783 million, extending runway into Q2 2028 [37] - Recent equity raise of $173 million to support TCE portfolio [37] Strategic Considerations - **Internal vs. External Development**: - Decisions made on a case-by-case basis, considering market size, competitive landscape, and required capabilities [39][40] Conclusion - Vir Biotechnology is positioned strongly in the oncology space with promising data for VIR-5500 and a strategic partnership with Astellas that enhances its development capabilities and financial flexibility. The company is also making significant strides in addressing unmet needs in HDV treatment, with a robust pipeline and a clear strategy for future growth.

Core Viewpoint - Vir Biotechnology has entered into an exclusive licensing agreement with Norgine Pharma UK Limited for the commercial rights to the combination treatment of tobevibart and elebsiran for chronic hepatitis delta (CHD) in Europe, Australia, and New Zealand, which is expected to enhance the commercialization efforts and extend the company's financial runway into Q4 2027 [1][2][5]. Financial Terms - Vir Biotechnology will receive an initial reimbursement payment of EUR 55 million and is eligible for up to EUR 495 million in clinical, regulatory, and sales milestones, along with tiered royalties on net sales in the licensed territory [1]. - Norgine will contribute approximately 25% of the ongoing external clinical development costs for the ECLIPSE registrational program [1]. Product Development - The combination of tobevibart and elebsiran is being evaluated as a potentially first-of-its-kind therapy for CHD, utilizing a human monoclonal antibody and a small interfering RNA (siRNA) to disrupt the viral lifecycle [2]. - Enrollment for the ECLIPSE 3 trial has been completed, which is a Phase 2b head-to-head trial comparing the combination treatment with bulevirtide in bulevirtide-naïve patients [3]. Clinical Data - Data from the Phase 2 SOLSTICE trial indicated that 66% of participants receiving the combination treatment achieved hepatitis delta virus (HDV) RNA target not detected (TND) after 48 weeks, with a high proportion of TND observed in patients with cirrhosis [4]. Regulatory Designations - The combination treatment has received Breakthrough Therapy and Fast Track designations from the U.S. FDA, as well as Priority Medicines (PRIME) and orphan drug designations from the European Medicines Agency (EMA) [9]. Market Context - Chronic Hepatitis Delta (CHD) is recognized as the most severe form of chronic viral hepatitis, with no approved treatments currently available in the U.S. and limited options in the European Union and globally [10].